Studies patient journeys and outcomes in transthyretin amyloidosis
Collects real-world records of people with ATTR amyloidosis, observing their care and outcomes.
Key facts
- Who runs it
- AstraZeneca
- Where
- Berlin, GermanySee the siteAlso in 10 other countries, 28 sites
- Trial code
- Registry title
- OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
- Status
- Recruiting
- People taking part
- 52,121 people, planned
- Started
- 21 Aug 2023
- Planned end
- 2 Nov 2026
- Type of study
- Observational, 6 groups
- Record updated
- 9 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with ATTR amyloidosis. It uses existing health records to study their disease, treatment and outcomes.
- Age
- Older than 18 years
- Sex
- Women and men
- Biomarker or test result
- A diagnosis code for amyloidosis, or a claim for ATTR-specific treatment, or a positive biopsy for amyloidosis with positive ATTR immunostaining.
Main reasons for not taking part
- Signs of primary (AL) amyloidosis
- Signs of secondary (AA) amyloidosis
- At least one claim or procedure code for a stem cell transplant
- Two or more claims or procedure codes for chemotherapy and autoimmune disease drugs that may treat AL or AA amyloidosis
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Patients aged >18 years at study index date AND
- A reported diagnosis code for amyloidosis OR
- A claim for ATTR-specific treatment OR
- A positive biopsy for amyloidosis and positive immunostaining result of biopsy for ATTR
Who cannot take part
- At least one claim/procedure code for stem cell transplant or at least two claims/procedure codes for chemotherapy and autoimmune disease drugs which may represent AL (primary) or AA (secondary) amyloidosis treatments
- Evidence of primary (AL) and secondary (AA) amyloidosis AND/OR
Where in Germany
Also in 10 other countries, 28 sites
- BerlinHospital not named in the registryNo longer taking part
About the trial
What the trial wants to find out
The overall aim of this observational study is to generate real-world evidence on the pre- and post-diagnosis disease journeys, including baseline characteristics, treatment patterns and selected clinical, economic, and humanistic outcomes (for example Health Related Quality of Life (HRQoL), Neuropathy impairment score, activities of daily living (ADL) assessments) in patients with ATTR amyloidosis, and to better understand how the disease is presented.
The 6 groups in the trial
- ATTR cardiomyopathy
Patients with Transthyretin Amyloidosis Cardiomyopathy
- ATTR polyneuropathy
Patients with Transthyretin Amyloidosis Neuropathy
- ATTR unknown
Patients with ATTR unknown genotype
- ATTR with mixed phenotype
Patients with ATTR mixed phenotype
- ATTR wild type
Patients with Transthyretin Amyloidosis wild type
- ATTR hereditary
Patients with Transthyretin Hereditary
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- OverTTuRe: An Observational Multi-Country Study Collecting Real-World Secondary Data on the Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
- Plain-language title
- Studies patient journeys and outcomes in transthyretin amyloidosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Record updated
- 9 September 2026